Healthcare Market News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 92,
"returned": 10,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "09ee1326-cb4b-4767-9ec0-122f7ceb7cdf",
"title": "HSBC Cuts Zoetis Inc. (ZTS)’s Price Target To $140 From $180, Keeps Buy Rating",
"description": "Zoetis Inc. (NYSE:ZTS) is among the 11 Most Oversold S&P 500 Stocks Heading into 2026.",
"keywords": "",
"snippet": "Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!\n\nAI i...",
"url": "https://www.insidermonkey.com/blog/hsbc-cuts-zoetis-inc-ztss-price-target-to-140-from-180-keeps-buy-rating-1659445/",
"image_url": "https://d2gr5kl7dt2z3t.cloudfront.net/blog/wp-content/uploads/2023/12/15085306/PHT-insidermonkey-1702648383866.jpg",
"language": "en",
"published_at": "2025-12-13T03:58:49.000000Z",
"source": "insidermonkey.com",
"relevance_score": null,
"entities": [
{
"symbol": "ZTS",
"name": "Zoetis Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 77.3087,
"sentiment_score": -0.296,
"highlights": [
{
"highlight": "HSBC Cuts <em>Zoetis</em> <em>Inc</em>. (ZTS)’s Price Target To $140 From $180, Keeps Buy Rating",
"sentiment": -0.296,
"highlighted_in": "title"
}
]
},
{
"symbol": "ZOE.DE",
"name": "Zoetis Inc.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 77.3045,
"sentiment_score": -0.296,
"highlights": [
{
"highlight": "HSBC Cuts <em>Zoetis</em> <em>Inc</em>. (ZTS)’s Price Target To $140 From $180, Keeps Buy Rating",
"sentiment": -0.296,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "cfda58e9-7c1b-4128-811f-9277e44bb72b",
"title": "Johnson & Johnson ordered to pay $40 million to two women in latest talc trial",
"description": "Johnson & Johnson ordered to pay $40 million for talc-related ovarian cancer, with plans to appeal the jury's verdict.",
"keywords": "",
"snippet": "A California jury in the U.S. on Friday (December 12, 2025) awarded $40 million to two women who said Johnson & Johnson’s baby powder was to blame for their o...",
"url": "https://www.thehindu.com/business/Industry/johnson-johnson-ordered-to-pay-40-million-to-two-women-in-latest-talc-trial/article70391440.ece",
"image_url": "https://th-i.thgim.com/public/incoming/mmdecg/article70391444.ece/alternates/LANDSCAPE_1200/2025-10-07T151240Z_8809158_RC227HAJFMBO_RTRMADP_3_J-J-TALC-VERDICT.JPG",
"language": "en",
"published_at": "2025-12-13T03:03:51.000000Z",
"source": "thehindu.com",
"relevance_score": null,
"entities": [
{
"symbol": "JNJ",
"name": "Johnson & Johnson",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 84.908356,
"sentiment_score": -0.44225,
"highlights": [
{
"highlight": "The jury in Los Angeles Superior Court a[+223 characters]",
"sentiment": -0.6124,
"highlighted_in": "main_text"
},
{
"highlight": "In closing arguments that Reuters viewed[+327 characters]",
"sentiment": -0.7579,
"highlighted_in": "main_text"
},
{
"highlight": "No evidence, says company\n\nAllison Brown[+100 characters]",
"sentiment": -0.296,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Johnson</em> & <em>Johnson</em> ordered to pay $40 million to two women in latest talc trial",
"sentiment": -0.1027,
"highlighted_in": "title"
}
]
},
{
"symbol": "DJNJ2.BA",
"name": "Johnson & Johnson",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "Healthcare",
"match_score": 84.90213,
"sentiment_score": -0.44225,
"highlights": [
{
"highlight": "The jury in Los Angeles Superior Court a[+223 characters]",
"sentiment": -0.6124,
"highlighted_in": "main_text"
},
{
"highlight": "In closing arguments that Reuters viewed[+327 characters]",
"sentiment": -0.7579,
"highlighted_in": "main_text"
},
{
"highlight": "No evidence, says company\n\nAllison Brown[+100 characters]",
"sentiment": -0.296,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Johnson</em> & <em>Johnson</em> ordered to pay $40 million to two women in latest talc trial",
"sentiment": -0.1027,
"highlighted_in": "title"
}
]
},
{
"symbol": "DJNJ3.BA",
"name": "Johnson & Johnson",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "Healthcare",
"match_score": 84.90213,
"sentiment_score": -0.44225,
"highlights": [
{
"highlight": "The jury in Los Angeles Superior Court a[+223 characters]",
"sentiment": -0.6124,
"highlighted_in": "main_text"
},
{
"highlight": "In closing arguments that Reuters viewed[+327 characters]",
"sentiment": -0.7579,
"highlighted_in": "main_text"
},
{
"highlight": "No evidence, says company\n\nAllison Brown[+100 characters]",
"sentiment": -0.296,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Johnson</em> & <em>Johnson</em> ordered to pay $40 million to two women in latest talc trial",
"sentiment": -0.1027,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "cf5f0455-4f27-4370-bc87-a10476f190e6",
"title": "Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)",
"description": "First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythmFDA approval in PSVT enables development of AFib-RVR under sNDA pathwayMilestone well-capitalized to launch and commercialize CARDAMYST with existing capital and royalty financingConference call and webcast December 15, 8:00 a.m. ET MONTREAL and CHARLOTTE, N.C., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that the U.S. Food and Drug Administration (FDA) approved its first commercial product, CARDAMYST™ (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. This approval marks the first time that more than two million Americans with PSVT will have a rapid-acting treatment option they can self-administer outside the emergency department or other healthcare setting. CARDAMYST is expected to be available in retail pharmacies in the first quarter of 2026.",
"keywords": "Milestone, Receives, FDA, Approval, of, CARDAMYST™, (etripamil), as, First, and, Only, Self-Administered, Nasal, Spray, for, Adults, with, Paroxysmal, Supraventricular, Tachycardia, (PSVT)",
"snippet": "First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT\n\nNovel nasal spray designed to rapidly resolve episodes of PSVT and restor...",
"url": "https://www.manilatimes.net/2025/12/13/tmt-newswire/globenewswire/milestone-receives-fda-approval-of-cardamyst-etripamil-as-first-and-only-self-administered-nasal-spray-for-adults-with-paroxysmal-supraventricular-tachycardia-psvt/2242773",
"image_url": "https://www.manilatimes.net/manilatimes/uploads/images/2025/12/13/865939.png",
"language": "en",
"published_at": "2025-12-13T01:06:23.000000Z",
"source": "manilatimes.net",
"relevance_score": null,
"entities": [
{
"symbol": "MIST",
"name": "Milestone Pharmaceuticals Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 26.17947,
"sentiment_score": 0.694533,
"highlights": [
{
"highlight": "(<em>Nasdaq</em>: <em>MIST</em>) today a[+286 characters]",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "\"CARDAMYST is a novel at-the-ready treat[+243 characters]",
"sentiment": 0.7579,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Milestone</em> <em>Pharmaceuti[+255 characters]",
"sentiment": 0.9042,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "f3b11c18-c91b-463a-873c-3b34db26a958",
"title": "Annual Changes to the Nasdaq-100 Index®",
"description": "NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq-100 Index® (NDX®), which will become effective prior to market open on Monday, December 22, 2025.",
"keywords": "Annual, Changes, to, the, Nasdaq-100, Index®",
"snippet": "NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq-100 Index® (NDX®), wh...",
"url": "https://www.manilatimes.net/2025/12/13/tmt-newswire/globenewswire/annual-changes-to-the-nasdaq-100-index/2242771",
"image_url": "https://www.manilatimes.net/manilatimes/uploads/images/2025/12/13/865938.jpg",
"language": "en",
"published_at": "2025-12-13T01:06:11.000000Z",
"source": "manilatimes.net",
"relevance_score": null,
"entities": [
{
"symbol": "ALNY",
"name": "Alnylam Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 84.19694,
"sentiment_score": 0.255,
"highlights": [
{
"highlight": "The following six companies will be adde[+301 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "delivered to your inbox Sign up for The [+325 characters]",
"sentiment": 0.765,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Pharmaceuticals</em>, <em>Inc</em>. [+328 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "BIIB",
"name": "Biogen Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 55.906815,
"sentiment_score": 0,
"highlights": [
{
"highlight": "As a result of the reconstitution, the f[+305 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "INSM",
"name": "Insmed Incorporated",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 82.37379,
"sentiment_score": 0.4633,
"highlights": [
{
"highlight": "(Nasdaq: ALNY), Ferrovial SE (Nasdaq: FE[+206 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": ", I acknowledge that I have read and agr[+325 characters]",
"sentiment": 0.765,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Incorporated</em> - https://insmed.c[+288 characters]",
"sentiment": 0.6249,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "BIIB.MX",
"name": "Biogen Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 18.755379,
"sentiment_score": 0,
"highlights": [
{
"highlight": "As a result of the reconstitution, the f[+287 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "A1LN34.SA",
"name": "Alnylam Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 45.90784,
"sentiment_score": 0.255,
"highlights": [
{
"highlight": "The following six companies will be adde[+283 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "delivered to your inbox Sign up for The [+325 characters]",
"sentiment": 0.765,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Pharmaceuticals</em>, <em>Inc</em>. [+328 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "BIIB.BA",
"name": "Biogen Inc.",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "Healthcare",
"match_score": 18.756556,
"sentiment_score": 0,
"highlights": [
{
"highlight": "As a result of the reconstitution, the f[+287 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "IDP.DE",
"name": "Biogen Inc.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 18.756207,
"sentiment_score": 0,
"highlights": [
{
"highlight": "As a result of the reconstitution, the f[+287 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "DUL.DE",
"name": "Alnylam Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 45.925747,
"sentiment_score": 0.255,
"highlights": [
{
"highlight": "The following six companies will be adde[+283 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "delivered to your inbox Sign up for The [+325 characters]",
"sentiment": 0.765,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Pharmaceuticals</em>, <em>Inc</em>. [+328 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "3f2b612c-a9e1-44dd-ad89-bd3b02559460",
"title": "米国株式市場は下落 ブロードコム急落でAI・半導体関連に売り波及",
"description": "「シカゴ日経平均先物（ＣＭＥ）」（12日）。",
"keywords": "マーケット, 海外株式市場, ",
"snippet": "*09:43JST 米国株式市場は下落 ブロードコム急落でAI・半導体関連に売り波及\n\n「シカゴ日経平均先物（ＣＭＥ）」（12日?...",
"url": "https://www.zaikei.co.jp/article/20251213/836206.html",
"image_url": "http://www.zaikei.co.jp/images/zaikei_og_image.jpg",
"language": "ja",
"published_at": "2025-12-13T00:43:15.000000Z",
"source": "zaikei.co.jp",
"relevance_score": null,
"entities": [
{
"symbol": "HOCPY",
"name": "HOYA Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 12.378784,
"sentiment_score": null,
"highlights": [
{
"highlight": "4\n\n7267 (HMC.N) 本田技研工業 30.93[+410 characters]",
"sentiment": null,
"highlighted_in": "main_text"
},
{
"highlight": ") <em>HOYA</em> 151.44 -2.04 23552 -34\n\n[+385 characters]",
"sentiment": null,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "8c6cd408-afc6-403d-b1f5-33a0f19732b2",
"title": "Genesis Healthcare Remains Committed to Securing Longterm Stability",
"description": "The skilled nursing, assisted and senior living provider reiterates dedication to a financial restructuring process centered around current and future patients, residents and staff",
"keywords": "Genesis, Healthcare, Remains, Committed, to, Securing, Longterm, Stability",
"snippet": "The skilled nursing, assisted and senior living provider reiterates dedication to a financial restructuring process centered around current and future patients,...",
"url": "https://www.manilatimes.net/2025/12/13/tmt-newswire/globenewswire/genesis-healthcare-remains-committed-to-securing-longterm-stability/2242761",
"image_url": "https://www.manilatimes.net/manilatimes/uploads/images/2025/12/13/865927.jpg",
"language": "en",
"published_at": "2025-12-12T23:25:40.000000Z",
"source": "manilatimes.net",
"relevance_score": null,
"entities": [
{
"symbol": "GEN",
"name": "Genesis Healthcare, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 82.95287,
"sentiment_score": 0.474729,
"highlights": [
{
"highlight": "., Dec. 11 to reopen the auction process[+345 characters]",
"sentiment": 0.5994,
"highlighted_in": "main_text"
},
{
"highlight": "Get the latest news\n\ndelivered to your i[+333 characters]",
"sentiment": 0.7845,
"highlighted_in": "main_text"
},
{
"highlight": "favorable rating for relationship with s[+334 characters]",
"sentiment": 0.9186,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Healthcare</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "ABOUT <em>GENESIS</em> <em>HEALTHCARE</e[+187 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Its subsidiaries also specialize in cont[+257 characters]",
"sentiment": 0.4939,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Genesis</em> <em>Healthcare</em> Remains Committed to Securing Longterm Stability",
"sentiment": 0.5267,
"highlighted_in": "title"
}
]
},
{
"symbol": "GENN",
"name": "Genesis Healthcare, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 82.95154,
"sentiment_score": 0.474729,
"highlights": [
{
"highlight": "., Dec. 11 to reopen the auction process[+345 characters]",
"sentiment": 0.5994,
"highlighted_in": "main_text"
},
{
"highlight": "Get the latest news\n\ndelivered to your i[+333 characters]",
"sentiment": 0.7845,
"highlighted_in": "main_text"
},
{
"highlight": "favorable rating for relationship with s[+334 characters]",
"sentiment": 0.9186,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Healthcare</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "ABOUT <em>GENESIS</em> <em>HEALTHCARE</e[+187 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Its subsidiaries also specialize in cont[+257 characters]",
"sentiment": 0.4939,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Genesis</em> <em>Healthcare</em> Remains Committed to Securing Longterm Stability",
"sentiment": 0.5267,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "5bba0bde-1ab2-4e4a-81c1-49f8e1457897",
"title": "Xenon Pharmaceuticals Inc. (XENE) Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch Preparation - Slideshow (NASDAQ:XENE) 2025-12-12",
"description": "2025-12-12. The following slide deck was published by Xenon Pharmaceuticals Inc.",
"keywords": "",
"snippet": "To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.\n\nIf you have an ad-blocker enabled you may be blocked from ...",
"url": "https://seekingalpha.com/article/4853077-xenon-pharmaceuticals-inc-xene-discusses-latest-phase-iii-updates-for-azetukalner-in-epilepsy",
"image_url": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
"language": "en",
"published_at": "2025-12-12T23:14:18.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "XENE",
"name": "Xenon Pharmaceuticals Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 133.93362,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>Xenon</em> <em>Pharmaceuticals</em> <em>Inc</em>. (XENE) Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch Preparation - Slideshow (<em>NASDAQ:XENE</em>) 2025-12-12",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "61f49690-9010-493b-afc5-af27b7f4ead8",
"title": "Tech stocks weigh on Canadian, U.S. markets while pot stocks surge – Investment Executive",
"description": "",
"keywords": "",
"snippet": "Within Canada’s tech sector, he said Celestica Inc. was impacted by some of the “AI skepticism.” Celestica shares finished 12.92% lower on the day, taking...",
"url": "https://www.investmentexecutive.com/uncategorized/tech-stocks-weigh-on-canadian-u-s-markets-while-pot-stocks-surge/",
"image_url": "https://www.investmentexecutive.com/wp-content/uploads/sites/3/2018/01/cropped-favicon-1-32x32.png",
"language": "en",
"published_at": "2025-12-12T22:39:26.000000Z",
"source": "investmentexecutive.com",
"relevance_score": null,
"entities": [
{
"symbol": "APHA",
"name": "Tilray, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 15.246077,
"sentiment_score": 0.7785,
"highlights": [
{
"highlight": "Shares of <em>Tilray</em> Brands Inc. ga[+317 characters]",
"sentiment": 0.7785,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "TLRY",
"name": "Tilray, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 15.246082,
"sentiment_score": 0.7785,
"highlights": [
{
"highlight": "Shares of <em>Tilray</em> Brands Inc. ga[+317 characters]",
"sentiment": 0.7785,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "CGC",
"name": "Canopy Growth Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 17.38261,
"sentiment_score": 0.7188,
"highlights": [
{
"highlight": "Shares of Tilray Brands Inc. gained 44.3[+326 characters]",
"sentiment": 0.7188,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "ACB",
"name": "Aurora Cannabis Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 32.001846,
"sentiment_score": 0.7395,
"highlights": [
{
"highlight": "<em>Aurora</em> <em>Cannabis</em> <em>In[+296 characters]",
"sentiment": 0.7395,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "ACB.TO",
"name": "Aurora Cannabis Inc.",
"exchange": null,
"exchange_long": null,
"country": "ca",
"type": "equity",
"industry": "Healthcare",
"match_score": 38.637947,
"sentiment_score": 0.7395,
"highlights": [
{
"highlight": "<em>Aurora</em> <em>Cannabis</em> <em>In[+296 characters]",
"sentiment": 0.7395,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "APHA.TO",
"name": "Tilray, Inc.",
"exchange": null,
"exchange_long": null,
"country": "ca",
"type": "equity",
"industry": "Healthcare",
"match_score": 17.534843,
"sentiment_score": 0.7785,
"highlights": [
{
"highlight": "Shares of <em>Tilray</em> Brands Inc. ga[+317 characters]",
"sentiment": 0.7785,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "WEED.TO",
"name": "Canopy Growth Corporation",
"exchange": null,
"exchange_long": null,
"country": "ca",
"type": "equity",
"industry": "Healthcare",
"match_score": 19.672821,
"sentiment_score": 0.7188,
"highlights": [
{
"highlight": "Shares of Tilray Brands Inc. gained 44.3[+326 characters]",
"sentiment": 0.7188,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "TLRY.TO",
"name": "TILRAY INC",
"exchange": null,
"exchange_long": null,
"country": "ca",
"type": "equity",
"industry": "Healthcare",
"match_score": 17.534088,
"sentiment_score": 0.7785,
"highlights": [
{
"highlight": "Shares of <em>Tilray</em> Brands Inc. ga[+317 characters]",
"sentiment": 0.7785,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "72677dc6-1306-4444-aeb1-b17197ebf726",
"title": "UnitedHealth: A Long-Term Compounder Worth Holding Through Any Cycle (NYSE:UNH)",
"description": "UnitedHealth Group Incorporated is rated a Strong Buy with a $400 price target, reflecting 19% upside. Learn more about UNH stock here.",
"keywords": "",
"snippet": "Following my previous article on UnitedHealth Group Incorporated ( UNH ), the stock rebounded from undervalued levels and appreciated by 10%. Over roughly the p...",
"url": "https://seekingalpha.com/article/4853054-unitedhealth-a-long-term-compounder-worth-holding-through-any-cycle",
"image_url": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2181504623/image_2181504623.jpg?io=getty-c-w1536",
"language": "en",
"published_at": "2025-12-12T22:08:55.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "UNH",
"name": "UnitedHealth Group Incorporated",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 72.05829,
"sentiment_score": 0.36845,
"highlights": [
{
"highlight": "Following my previous article on <em>Uni[+128 characters]",
"sentiment": 0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "UnitedHealth: A Long-Term Compounder Worth Holding Through Any Cycle (<em>NYSE:UNH</em>)",
"sentiment": 0.2263,
"highlighted_in": "title"
}
]
},
{
"symbol": "UNHH34.SA",
"name": "UnitedHealth Group Incorporated",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 35.61336,
"sentiment_score": 0.5106,
"highlights": [
{
"highlight": "Following my previous article on <em>Uni[+128 characters]",
"sentiment": 0.5106,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "UNH.DE",
"name": "UnitedHealth Group Incorporated",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 35.614437,
"sentiment_score": 0.5106,
"highlights": [
{
"highlight": "Following my previous article on <em>Uni[+128 characters]",
"sentiment": 0.5106,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "UNH.MX",
"name": "UnitedHealth Group Incorporated",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 35.614513,
"sentiment_score": 0.5106,
"highlights": [
{
"highlight": "Following my previous article on <em>Uni[+128 characters]",
"sentiment": 0.5106,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "ce01ea1d-15bc-407d-ba05-6bff6e0f24d7",
"title": "Extendicare Announces December 2025 Dividend of C$0.042 per Share",
"description": "MARKHAM, Ontario, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. ('Extendicare” or the 'Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.042 per common share of the Company for the month of December 2025, which is payable on January 15, 2026 to shareholders of record at the close of business on December 31, 2025. This dividend is designated as an 'eligible dividend” within the meaning of the Income Tax Act (Canada).",
"keywords": "Extendicare, Announces, December, 2025, Dividend, of, C$0.042, per, Share",
"snippet": "MARKHAM, Ontario, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (\"Extendicare” or the \"Company”) (TSX: EXE) announced that it has declared a cash divid...",
"url": "https://www.manilatimes.net/2025/12/13/tmt-newswire/globenewswire/extendicare-announces-december-2025-dividend-of-c0042-per-share/2242747",
"image_url": "https://www.manilatimes.net/manilatimes/uploads/images/2025/12/13/865907.jpg",
"language": "en",
"published_at": "2025-12-12T22:06:12.000000Z",
"source": "manilatimes.net",
"relevance_score": null,
"entities": [
{
"symbol": "EXETF",
"name": "Extendicare Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 58.06456,
"sentiment_score": 0.462414,
"highlights": [
{
"highlight": "MARKHAM, Ontario, Dec. 12, 2025 (GLOBE N[+335 characters]",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Extendicare</em>\n\n<em>Extendic[+193 characters]",
"sentiment": 0.4939,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Extendicare</em> proudly employs app[+164 characters]",
"sentiment": 0.9589,
"highlighted_in": "main_text"
},
{
"highlight": "Forward-looking Statements\n\nInformation [+336 characters]",
"sentiment": 0.5349,
"highlighted_in": "main_text"
},
{
"highlight": "Further information can be found in the [+179 characters]",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Get the latest news\n\ndelivered to your i[+209 characters]",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Extendicare</em> Announces December 2025 Dividend of C$0.042 per Share",
"sentiment": 0.296,
"highlighted_in": "title"
}
]
},
{
"symbol": "EXE.TO",
"name": "Extendicare Inc.",
"exchange": null,
"exchange_long": null,
"country": "ca",
"type": "equity",
"industry": "Healthcare",
"match_score": 79.2222,
"sentiment_score": 0.462414,
"highlights": [
{
"highlight": "MARKHAM, Ontario, Dec. 12, 2025 (GLOBE N[+353 characters]",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Extendicare</em>\n\n<em>Extendic[+193 characters]",
"sentiment": 0.4939,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Extendicare</em> proudly employs app[+164 characters]",
"sentiment": 0.9589,
"highlighted_in": "main_text"
},
{
"highlight": "Forward-looking Statements\n\nInformation [+336 characters]",
"sentiment": 0.5349,
"highlighted_in": "main_text"
},
{
"highlight": "Further information can be found in the [+179 characters]",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Get the latest news\n\ndelivered to your i[+209 characters]",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Extendicare</em> Announces December 2025 Dividend of C$0.042 per Share",
"sentiment": 0.296,
"highlighted_in": "title"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "Healthcare",
"total_documents": 214,
"sentiment_avg": 0.28794212448632434
}
]
}
Other details
Entity count
- 11,338